Wedbush Equities Analysts Cut Earnings Estimates for Biogen

Biogen Inc. (NASDAQ:BIIB) – Equities research analysts at Wedbush reduced their Q1 2025 earnings estimates for Biogen in a research note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $3.51 per share for the quarter, down from their prior forecast of $3.82. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen’s Q4 2026 earnings at $3.97 EPS, FY2026 earnings at $17.02 EPS and FY2027 earnings at $17.83 EPS.

A number of other brokerages have also recently weighed in on BIIB. William Blair reissued an “outperform” rating on shares of Biogen in a research note on Monday, January 13th. Truist Financial reduced their price objective on Biogen from $220.00 to $210.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. StockNews.com downgraded shares of Biogen from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 28th. Sanford C. Bernstein assumed coverage on shares of Biogen in a research report on Tuesday, February 11th. They issued a “market perform” rating and a $160.00 price objective for the company. Finally, The Goldman Sachs Group cut their price target on Biogen from $281.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Eighteen analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $213.15.

Biogen Trading Up 2.9 %

NASDAQ:BIIB opened at $118.61 on Thursday. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $17.36 billion, a PE ratio of 10.60, a price-to-earnings-growth ratio of 1.51 and a beta of 0.06. The stock has a fifty day simple moving average of $134.29 and a 200-day simple moving average of $151.69. Biogen has a 52-week low of $110.04 and a 52-week high of $238.00.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.87% and a return on equity of 14.98%.

Hedge Funds Weigh In On Biogen

Large investors have recently made changes to their positions in the business. Larson Financial Group LLC raised its position in shares of Biogen by 640.9% during the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 141 shares during the period. Lee Danner & Bass Inc. acquired a new stake in shares of Biogen in the fourth quarter worth $25,000. Opal Wealth Advisors LLC purchased a new position in shares of Biogen during the first quarter valued at $26,000. Colonial Trust Co SC raised its position in Biogen by 9,300.0% during the fourth quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 186 shares during the period. Finally, OFI Invest Asset Management purchased a new stake in Biogen in the 4th quarter worth about $32,000. Institutional investors own 87.93% of the company’s stock.

Insiders Place Their Bets

In other news, Director Stephen A. Sherwin sold 8,760 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the sale, the director now owns 11,318 shares of the company’s stock, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.